Addressing an important challenge faced: Balancing speed and quality in antibody lead identification: Can emerging technologies deliver both?
22 Sep 2025
Lead Identification & Optimization
- Can large-scale screening platforms capture functional and developability complexity, or are we missing key signals?
- How can startups extract early, high-value insights without overspending, and when is it smarter to go broad vs. deep when timelines and budgets are tight?
- Are current discovery tools keeping pace with the evolving complexity of antibody formats like bispecifics, conditionals, and novel scaffolds?
- How do we align early discovery with downstream CMC and partner expectations to avoid roadblocks at IND or due diligence?
- What level of early developability assessment is essential and how do we balance speed with downstream manufacturability?
- Are AI predictions mature enough to guide early lead decisions or just directional?
